A 200% tariff rate — even with a delay — will have a detrimental effect on drug prices and profit margins, analysts warn.

In the first placebo-controlled study of vaporized cannabis for acute migraine, patients report greater relief from pain and ...

Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...

LLY has slid 15.7% over the past year, but surging demand for Mounjaro and Zepbound could revive the stock's momentum.

Eli Lilly’s Zepbound transformed weight loss drug market since debut 18 months ago 4.5 million people reportedly taking Lilly ...

Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, ...

ASX health stocks fall o.92% over past five days as US President Donald Trump renews threat to impose tariffs on pharmaceutical imports.

Approval was based on results from the Phase IIIb TRAILBLAZER-ALZ 6 trial, which showed that Kisunla achieved comparable ...

Adults with obesity were more likely to achieve a 10% or greater weight loss at 1 year if they continued using their ...

Along with announcing a 50% tariff on copper imports, The POTUS threatened to levy tariffs as high as 200% on pharmaceutical ...

Caitlin Clark Makes Exciting Announcement on Thursday originally appeared on Athlon Sports. Indiana Fever point guard Caitlin ...

The trove of more than 200 letters is part of a pledge of transparency from the agency, with the intention to increase public ...